PHBI - Pharmagreen Biotech Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.3400
-0.0100 (-2.86%)
At close: 2:47PM EST
Stock chart is not supported by your current browser
Previous Close0.3500
Open0.3600
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3200 - 0.3600
52 Week Range0.2700 - 3.0000
Volume2,331
Avg. Volume16,352
Market Cap25.72M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0080
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Pharmagreen Selects ICF (Insulated Concrete Forms) Building Technology for the Construction of its Cannabis Biotech Complex Building Material

    CARSON CITY, NV, Jan. 16, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pharmagreen Biotech, Inc., (PHBI), is pleased to announce today that it signed a memorandum of understanding with Here to Serve Holding Corp., (HTSC) to provide consulting services and supply ICF building material (Insulated Concrete Forms) for the construction of Pharmagreen’s 63,000 square foot facility, the Cannabis Biotech Complex. The complex, which will take about 18 months to construct, makes use of cutting edge technologies in its engineering, water recycling and conservation techniques, as well as with its construction material resulting in a reduced carbon footprint and secure, uniquely advanced, eco-friendly and semi-automated tissue culture, clean-room laboratory, extraction, distillation and research facility.

  • GlobeNewswire

    Pharmagreen Issues Statement On Potential Stock Promotion

    CARSON CITY, NV, Dec. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), a company specializing in the development of tissue cultured starter plantlets for the hemp industry, today announced that on December 16, 2019 it was made aware OTC Markets Group added a Megaphone next to the Company’s trading symbol, representing potential promotional activities surrounding the Company’s common stock. Promotional activities generally may involve promotional newsletters, styled as “paid announcements”. The paid announcements generally encourage investors to put the Company’s common stock on their watch list.

  • GlobeNewswire

    Pharmagreen Provides Update

    CARSON CITY, NV, Dec. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), is pleased to provide a company development update. The company has secured significant credit facility to date and plans to use the funds to move forward with its projects development to build a state of the art all year round greenhouse and a tissue cultured starter plantlet production facility. The all year round greenhouse was added to the company’s plans for a first build out as time to complete construction is less than six months and revenue producing within 3 months of operations.

  • GlobeNewswire

    Pharmagreen Closes $10 Million Equity Purchase Agreement

    CARSON CITY, NV, Dec. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), is pleased to announce today that the company executed all the required documents for an Equity Purchase Agreement (the "Equity Agreement") with Oscaleta Partners LLC ("Oscaleta"), as stated earlier in the news release dated November 12, 2019, that should enable Pharmagreen to access capital over the next 2 years to support its current growth plans. The terms of the Equity Agreement will give Pharmagreen the right, but never the obligation, to sell to Oscaleta up to Ten Million Dollars’ worth of Pharmagreen’s registered common stock over an anticipated two-year period at times and in amounts that Pharmagreen deems appropriate. Now that the Equity Agreement is fully executed, the company has started immediate work on the registration statement.

  • Pharmagreen Signs Term Sheet for $10 Million Equity Purchase Agreement
    Newsfile

    Pharmagreen Signs Term Sheet for $10 Million Equity Purchase Agreement

    Carson City, Nevada--(Newsfile Corp. - November 12, 2019) - Pharmagreen Biotech, Inc. (OTC PINK: PHBI), is pleased to announce today that the company signed a term sheet for an Equity Purchase Agreement (the "Equity Agreement") with Oscaleta Partners LLC ("Oscaleta"), that should enable Pharmagreen to access capital over the next 2 years to support its current growth plans. The terms of the Equity Agreement will give Pharmagreen the right, but NEVER THE OBLIGATION, ...

  • GlobeNewswire

    Pharmagreen Signs a LOI for Supply of CBD Dana Hemp Starter Plantlets

    CARSON CITY, NV, Oct. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), is pleased to announce that its Canadian subsidiary, WFS Pharmagreen Inc., has signed a Letter of Intent with Carpere Inc. for the supply of “CBD Dana” hemp starter plantlets for the 2020 farming season and beyond. The Pharmagreen team is excited to work with Carpere to be their supplier of all female high CBD hemp starter plantlets to produce the highest quality high CBD flower tops as well as production of the CBD whole hemp oils and isolate. Carpere owns and manages farmland, on behalf of farmers, in excess of 100,000 acres throughout Canada.

  • GlobeNewswire

    SmallCap Sentinel: A Hundred Times Better

    Enter Pharmagreen Biotech (PHBI). Pharmagreen is intent on raising the bar in the cannabis space, both in the quality of cannabis produced and the efficiency of the growing method. The company is highly focused on the rapidly evolving CBD industry by developing supply chain for CBD hemp growers utilizing the CBD Dana hemp strain.

  • Pharmagreen Biotech Inc. Announces the Formation of Independent Advisory Board
    PR Newswire

    Pharmagreen Biotech Inc. Announces the Formation of Independent Advisory Board

    CARSON CITY, NV, Sept. 3, 2019 /PRNewswire/ - Pharmagreen Biotech, Inc., (PHBI), is pleased to announce the formation of its independent advisory board and welcomes Dr. Archer Baskerville from Virginia, United States, and Dr. Wladyslaw Wojcik from Saskatchewan, Canada to serve as advisory board members and advising the Company on developments in the medical industry regarding the adaptation of cannabinoid use, especially CBD in the treatment of individuals.  Both are currently practicing specialists in Cardiology and their professional insight will provide the company with very valuable data that will be used in future extraction and formulations of cannabinoids under the Pharmagreen brand. Pharmagreen is highly focused on the rapidly evolving CBD industry by developing supply chain for CBD hemp growers utilizing the CBD Dana hemp strain.

  • Pharmagreen Biotech Inc. selects Signify as its strategic technology partner and will be utilizing Philips LED Lighting technologies at its Cannabis Biotech Complex for its annual production of up to 12 million Tissue Culture Starter Plantlets for Cannabis licensed producers and high CBD hemp growers
    PR Newswire

    Pharmagreen Biotech Inc. selects Signify as its strategic technology partner and will be utilizing Philips LED Lighting technologies at its Cannabis Biotech Complex for its annual production of up to 12 million Tissue Culture Starter Plantlets for Cannabis licensed producers and high CBD hemp growers

    CARSON CITY, NV, July 23, 2019 /PRNewswire/ - Pharmagreen Biotech is pleased to announce it will use Signify's Philips GreenPower LED Lighting in our Cannabis Biotech Complex currently under development. The Cannabis Biotech Complex, located in Deroche, B.C., Canada once completed will be a high-tech, state of the art facility, and serve as a blueprint for additional future buildouts in United States and Internationally.  The strategic supply partnership with Signify's Philips LED lighting technology adds the high-tech value and opens the door for future cooperation in advancing solutions for the tissue culture industry.

  • PR Newswire

    Pharmagreen Biotech Inc. Announces that Registration Statement on Form S-1 has been Declared Effective - Pharmagreen is a Cannabis Company that is a producer of highest quality CBD Hemp Plantlets

    CARSON CITY, NV, July 18, 2019 /PRNewswire/ - Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), announced today that the Securities and Exchange Commission ("SEC") has declared effective the Company's registration on Form S-1 (file 333-230413) relating to the sale from treasury of up to 20,000,000 shares of the Company's Class A common stock at an issue price of $2 per share, and the resale of 4,051,725 common stock  that have been issued to the Selling Stockholders named in this registration statement. Pharmagreen will not receive any proceeds from the re-sale of the securities by the selling security stockholders.  Pharmagreen will receive the proceeds from the sale of the 20,000,000 shares issued out of treasury. The registration statement may be accessed through the SEC's website at www.sec.gov.

  • GlobeNewswire

    Pharmagreen Receives Positive News from Health Canada on its Cannabis License Application Submission

    CARSON CITY, NV, May 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Pharmagreen Biotech, Inc. (OTC PINKS: PHBI), is pleased to announce that its Canadian subsidiary, WFS Pharmagreen Inc., has received notification concerning WFS PHARMAGREEN INC.’s application submitted under the Cannabis Regulations to become a license holder. “Health Canada has completed a preliminary and high-level review of the license application. Based on the information assessed, Health Canada has no critical concerns with the application at this time.” This confirms that all the required information submitted to date has been accepted by Health Canada.